recombinant herpes zoster vaccine (CHO Cells)
/ MaxHealth Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 20, 2024
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
(clinicaltrials.gov)
- P2 | N=924 | Active, not recruiting | Sponsor: MAXVAX Biotechnology Limited Liability Company | Trial primary completion date: Feb 2024 ➔ Dec 2024
Trial primary completion date • Herpes Zoster • Varicella Zoster • IFNG • IL2 • TNFA
October 23, 2024
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
(clinicaltrials.gov)
- P3 | N=1200 | Not yet recruiting | Sponsor: MAXVAX Biotechnology Limited Liability Company
New P3 trial • Herpes Zoster • Varicella Zoster
October 19, 2023
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
(clinicaltrials.gov)
- P2 | N=924 | Active, not recruiting | Sponsor: MAXVAX Biotechnology Limited Liability Company | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Mar 2026 | Trial primary completion date: Sep 2025 ➔ Feb 2024
Enrollment closed • Trial completion date • Trial primary completion date • Herpes Zoster • Varicella Zoster • CD40LG • IL2
May 12, 2023
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
(clinicaltrials.gov)
- P2 | N=924 | Not yet recruiting | Sponsor: MAXVAX Biotechnology Limited Liability Company
New P2 trial • Herpes Zoster • Varicella Zoster • CD40LG • IL2
1 to 4
Of
4
Go to page
1